Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 42Lung Neoplasms 32Head and Neck Neoplasms 24Glioblastoma 24Squamous Cell Carcinoma of Head and Neck 22Breast Neoplasms 21Lymphoma 17Brain Neoplasms 17Rectal Neoplasms 16Prostatic Neoplasms 15Lymphoma, Non-Hodgkin 14Leukemia, Lymphocytic, Chronic, B-Cell 13Leukemia 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Lymphoma, Follicular 11Gliosarcoma 11Esophageal Neoplasms 11Central Nervous System Neoplasms 11Adenocarcinoma Of Esophagus 11Pancreatic Neoplasms 10Melanoma 10Lymphoma, Large B-Cell, Diffuse 10Hodgkin Disease 10Neoplasm Metastasis 9Multiple Myeloma 9Neoplasms, Plasma Cell 8Lymphoma, B-Cell, Marginal Zone 8Leukemia, Myeloid, Acute 8Burkitt Lymphoma 8Sarcoma 7

Interventions

Radiotherapy 1Oxaliplatin 1Lapatinib 1Fluorouracil 1Combined Modality Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × HER2 Positive Esophagogastric Cancer × Radiotherapy × Clear all
NCT01769508 2016-06-13

Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer

SCRI Development Innovations, LLC

Phase 2 Terminated
12 enrolled 8 charts
Gastrointestinal

HER2 Positive Esophagogastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡